title: Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
abstract: Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia. Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome. In this setting, administering a repeat course of induction shortly after completion of the first course, known as timed-sequential chemotherapy (TSC), has been tested and may lead to an improved long-term outcome. Whether these results are due to the biologic recruitment of cell cycle-specific agents is unknown. However, this strategy to intensify induction may lead to more profound myelosuppression and to potential toxicities. Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.
authors: Leukemia Unit, Hematology Department, Edouard Herriot Hospital, Lyon, France. xavier.thomas@chu-lyon.fr
authors: Xavier
authors: X
authors: Thomas
authors: Hervé
authors: H
authors: Dombret
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002453:Cell Cycle / Q000187:drug effects; D002648:Child; D003561:Cytarabine / Q000494:pharmacology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology; D011292:Premedication; D011379:Prognosis; D051381:Rats; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D005419:Flavonoids; D010880:Piperidines; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; C077990:alvocidib; D016178:Granulocyte-Macrophage Colony-Stimulating Factor